Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briga-PED
2024-513412-10-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label trial of brigatinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT) and Nonhematologic neoplasms (5 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities, Pharmacokinetics and 5 more. Planned start May 2022; status: authorised.
02
Drugs
brigatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-513412-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513412-10-00.